First Phase II data bode well for S*BIO's JAK2 inhibitor
This article was originally published in Scrip
Executive Summary
Positive data from the first Phase II clinical study with S*BIO's JAK2 inhibitor SB1518 support the further investigation of the oral small molecule for the treatment of symptomatic myelofibrosis (MF), the private Singapore venture has concluded.